Regenerative Medicine – Market Insights – United States

The US market for regenerative medicine therapies consists of relatively new products in expanding markets and emerging technologies that will form new segments. The market is expected to undergo enormous growth once the first products enter the market due to the high prices of these therapies and the large patient populations for the treatments, as well as their ability to address the unmet needs of patient populations with rare diseases for which there are few alternative treatments.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for regenerative medicine in the US across a 10-year period, with additional coverage through 2027 for some segments.

There are enormous market opportunities for gene and cell therapies.

How will prices and reimbursement impact the regenerative medicine market?

When will the majority of treatments come to market?

How many procedures will be performed by the end of the forecast period?

What challenges will companies face in terms of competing in these emerging segments?

There are currently very few approved regenerative medicine therapies in the US.

Which indications have the highest patient populations?

How quickly will treatments be adopted for different diseases?

There is a significant variety of diseases that can be treated by both gene and cell therapies.

For which indications will regenerative therapies become available first?

How will the companies that are first-to-market impact the regenerative medicine market as a whole?

What challenges will companies face in terms of competing in these emerging segments?